Today, we announced our Q3 2026 financial results and corporate highlights. Read more in our press release: bit.ly/4kzO1Jp
CAMP4 Therapeutics
@camp4tx
Advancing a pipeline of ASO-based, RNA-targeting therapeutics with the aim to restore healthy protein levels
36 Following 538 Followers 390 Posts
Latest posts 5
We look forward to connecting with investors and industry leaders at the upcoming @Stifel and Guggenheim Healthcare conferences to discuss our approach to addressing #HaploinsufficientDiseases like #SYNGAP1. Tune in to the webcasts & replays here: bit.ly/3UrYfjS
0:17
#ICYMI, our CFO, Kelly Gold, joined @MichaelBSpector for a @Nasdaq Amplify interview to discuss CAMP4’s novel drug discovery efforts in #HaploinsufficientDiseases & the role of strategic partnerships in advancing our mission. Watch here: bit.ly/4BnxuOz
Honored to join @Nasdaq to ring the Closing Bell as CAMP4 prepares to enter the clinic for #SYNGAP1-related disorder. A major milestone in advancing ASO therapeutics and a meaningful step toward potential treatments for #HaploinsufficientDiseases.
We’re excited to announce that we’ve received clearance from the European Medicines Agency to begin our Phase 1/2 clinical trial of CMP-002 in #SYNGAP1 patients in the European Union. Read more in our press release: bit.ly/4ii9ZiN
0:13